HemaCare Details Expanded GMP Capabilities at CAR-TCR Summit in Boston, MA
Facility Relocation and Expansion Offers Fully-Integrated GMP Cell Therapy Services
(Los Angeles, CA – September 4, 2018) HemaCare Corporation (OTCBB: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, today announces details of their expanded GMP capabilities at the annual CAR-TCR Summit on September 4-7, 2018. HemaCare will be relocating its operations and corporate headquarters to a larger, state-of-the-art facility with four GMP cleanrooms for expansion of GMP-compliant cells, tissues, and services. This new center of excellence will make HemaCare the first commercial provider of GMP human primary cells isolated from leukopaks collected onsite. These services will support the research, scientific, and clinical community by providing high-quality GMP cells in a reproducible manner which comply with both FDA and European Medicines Agency (EMA) regulations.
“Attending the CAR-TCR conference allows HemaCare the opportunity to reveal some of the future GMP capabilities debuting in 2018. We are excited by the overall growth of the cell therapy industry, and we have strategically expanded our capabilities to meet industry demand and continue to provide high-quality starting material to the leading cell and gene therapy companies in the world,” said Pete van der Wal, HemaCare’s President and CEO.
HemaCare’s GMP-compliant clean rooms will allow the following services to be performed onsite: collection, processing and isolation of GMP raw material and cells, processing of autologous patient material, and GMP-compliant cryopreservation and storage at the new biobanking facility. Flexible production environments and optimized process flow will enable HemaCare to address customers’ increasingly complex requirements and provide sufficient scalability to support their global customer base. GMP apheresis collection starting material from HemaCare’s extensive registry of recallable, reliable donors can be cryopreserved and shipped as needed for allogeneic cell therapy manufacturing allowing HemaCare to expand upon its recently launched unique cryopreserved leukopak offering.
“CAR-TCR Summit offers us an ideal opportunity to stay informed on the latest developments regarding T cell therapies. We look forward to meeting with our industry partners and cell therapy development customers to discuss current challenges in the industry. As a company, we hope to address many of these hurdles with our products and services offered from our new GMP facility,” said Dr. Dominic Clarke, HemaCare’s Global Head of Cell Therapy.
The 40,000-square foot facility will be located on an expansive corporate campus in the nearby San Fernando Valley, California.
Business Development Contact: